Heart failure (Q83475304)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Heart failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

William T Abraham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Henry Krum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

1 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

9667

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

941-955

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

Heart failure in sub-saharan Africa: time for action

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Natural history of asymptomatic left ventricular systolic dysfunction in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Epidemiology of diastolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Incidence and aetiology of heart failure; a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Long-Term Trends in the Incidence of and Survival with Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Trends in Heart Failure Incidence and Survival in a Community-Based Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Lifetime Risk for Developing Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Trends in prevalence and outcome of heart failure with preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The current cost of heart failure to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Predictors of costs of caring for elderly patients discharged with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Demographics and concomitant disorders in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Clinical epidemiology of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diabetes, left ventricular systolic dysfunction, and chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Role of diabetes in congestive heart failure: the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Assessing diagnosis in heart failure: which features are any use?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The role of cardiovascular MRI in heart failure and the cardiomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of exercise training in patients with congestive heart failure: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Coenzyme Q10 and exercise training in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Chronic heart failure and micronutrients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Wasting as independent risk factor for mortality in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

1 reference

7 January 2021

Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diuretic use, progressive heart failure, and death in patients in the DIG study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Association of serum digoxin concentration and outcomes in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

1 reference

7 January 2021

New developments in the pharmacological treatment of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Statins and chronic heart failure: do we need a large-scale outcome trial?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Rosuvastatin in older patients with systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Increased mortality after dronedarone therapy for severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Rhythm control versus rate control for atrial fibrillation and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Cardiac resynchronization in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The effect of cardiac resynchronization on morbidity and mortality in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Primary Prevention of Sudden Cardiac Death in Heart Failure: Will the Solution Be Shocking?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Sudden death prevention in patients with advanced ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Does bridging to transplantation with a left ventricular assist device adversely affect posttransplantation survival? A comparative analysis of mechanical versus inotropic support

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Long-term use of a left ventricular assist device for end-stage heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Current trends in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Mitral valve surgery in patients with poor left ventricular function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the L

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Noninvasive ventilation in acute cardiogenic pulmonary edema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Defining diastolic heart failure: a call for standardized diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diastolic heart failure: standard Doppler approach and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Heart failure with preserved systolic function. A different natural history?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Drug discovery for heart failure: a new era or the end of the pipeline?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

The role of nebulized morphine in managing dyspnea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Proteomics of the heart: unraveling disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Emerging role of pharmacogenomics in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Mesenchymal stem cells for cardiac regenerative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Skeletal myoblasts as a therapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

Gene therapy: targeting the myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960236-1

7 January 2021

10.1016/S0140-6736(09)60236-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19286093%20AND%20SRC:MED&resulttype=core&format=json